CTOs on the Move

Hysitron

www.hysitron.com

 
Hysitron, Inc is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.hysitron.com
  • 10025 Valley View Rd Ste 190
    Eden Prairie, MN USA 55344
  • Phone: 952.835.6366

Executives

Name Title Contact Details

Similar Companies

NXT-USA

NXT USA is a company that focuses on developing clinically validated branded ingredients that positively impact global health.

Medelis

Medelis is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

G and W Laboratories

Carl Greenblatt founded G&W Laboratories, Inc. in 1919 upon his return from military service as a pharmacist with US forces in World War I. While establishing a reputation as an innovative specialist in suppository dosage forms, Carl guided G&W Laboratories with an uncompromising commitment to product integrity and customer service. In 1945, Carl’s son, Burton, also a registered pharmacist, returned from military service in World War II and joined the small but growing company. During the post-war years, G&W expanded its product line beyond suppositories, into creams, ointments, gels and liquids. G&W moved to a larger state-of-the-art laboratory and production facility, which now exceeds 180,000 square feet in South Plainfield, New Jersey. Continuing the high ethical standards and customer focus established by Carl and his son Burton Greenblatt, G&W is still family owned and operated. Burton’s son, Ronald, who joined the company in 1978 and now serves as Chief Executive Officer; and Ronald’s son, Aaron, who joined the company in 2009 after earning his Pharm.D. In addition to strong family ties the family hired Kurt Orlofski, who joined G&W as President and Chief Operating Officer in 2009.

Tetraphase

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.

Highfive Vet Wholesale

Automated purchasing for vet clinics | Less mundane tasks. More time for your mission.